Skip to main content
OpenTrials
Completed

NCT Number: NCT02791542

Sorting and Expression Profiling of Airway Cells From Humans (The SEARCH Study)

This will be a single site, mechanistic study of asthmatic subjects and healthy, non-asthmatic controls involving a baseline characterization visit and a research bronchoscopy visit. We will identify differences in airway epithelial epigenetic enhancer signatures in asthma, by analyzing freshly isolated airway epithelial cells from healthy controls and from well-characterized subjects with asthma.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of California, San Francisco

San Francisco, California, 94143, United States

About this study

The airway epithelium is critical for normal lung function and changes in the epithelium are central to the development of asthma. Precise regulation of gene transcription is essential for airway epithelial cell differentiation and transcription changes lead to many abnormalities seen in asthma. Despite the dominant role of enhancers in regulating transcription, little is known about how these DNA regulatory elements control airway epithelial cell transcription or about how enhancer activity differs in asthma compared to health. Closing this knowledge gap will have a major impact on our understanding of normal epithelial development and asthma. In addition, enhancer-based approaches for reprogramming the airway epithelium promise to be powerful tools for dissecting mechanism that will set the stage for developing a new class of precisely targeted treatments for asthma. Our overall goals are to identify enhancers that are important in regulation of key airway epithelial cell genes, to determine how enhancer activity changes in asthma, and to develop approaches for targeting the activity of these enhancers.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(Healthy participants):

  • Male and female subjects between the ages of 18 and 70 years
  • Ability to provide written informed consent and ability to comply with the requirements of the study
  • No hyperreactivity to methacholine (PC20 FEV1 Methacholine >16 mg/mL)
  • No history of allergic rhinitis/seasonal allergies

Inclusion criteria

(Asthmatic participants):

  • Male and female subjects between the ages of 18 and 70 years
  • Ability to provide written informed consent and ability to comply with the requirements of the study
  • History of asthma
  • No use of oral or inhaled corticosteroids for the treatment of asthma during the past 6 weeks
  • Hyperreactivity to methacholine (PC20 FEV1 Methacholine < 8 mg/ml)

Exclusion criteria

The same exclusion criteria will apply to both Sub-studies.

  • Current smokers, defined by (a) >5 cigarettes smoked in past 12 months, and (b) ≤ 8 weeks since last time smoking; or former smokers who have a total smoking history ≥10 pack-years
  • Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study
  • Subjects with a history of lung disease other than asthma
  • Subjects with a history of a medical disease, which in the opinion of the Investigator may put the subject at extra risk from study-related procedures or because the disease may influence the results of the study
  • Prior esophageal hernia surgery.
  • Current participation in an investigational drug trial

Treatment and study plan

Primary outcomes

  1. Measure the genomic location of enhancers in genes previously found to be differentially expressed in asthma vs health using H3K27ac ChIP-seq and ATAC-seq on airway epithelial brushings.

    Time frame: Between 1-12 weeks

    We previously identified changes in epithelial gene expression in individuals with asthma. To identify candidate enhancers that account for these changes, we will use Drop-seq, ChIPseq and ATAC-seq to analyze freshly isolated airway epithelial cells from healthy controls and from well-characterized subjects with asthma.

  2. Assessment of persistence of signatures of airway inflammation

    Time frame: 1-12 weeks and at 10-14 months

    Perform epithelial brush gene expression profiling and sputum induction on longitudinal samples obtained at 12 months after the initial bronchoscopy, to assess stability of type-2 and non-type-2 pathways that are dysregulated in asthma. (Achieved via the PISA sub-study)

Secondary outcomes

  1. Measure gene expression by RNA sequencing in both airway brushes and BAL cells for assessment of non-type-2 pathways differentially expressed in asthma vs health.

    Time frame: Between 1-12 weeks

    Perform bronchoalveolar lavage (BAL) cell flow cytometry and epithelial brush gene expression profiling to look for non-type-2 pathways that are dysregulated in asthma.

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)
  • National Institute of Allergy and Infectious Diseases (NIAID)

Registry information

Acronym: SEARCH

Important dates

Study start
2017
Primary completion
2023
Study completion
2023
First posted
Jun 6, 2016
Registry last updated
Feb 5, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.